company background image
6612

ICARES Medicus TPEX:6612 Stock Report

Last Price

NT$84.80

Market Cap

NT$2.9b

7D

-3.0%

1Y

32.7%

Updated

27 Sep, 2022

Data

Company Financials
6612 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

6612 Stock Overview

ICARES Medicus, Inc., a nano-medical material company, focuses on the research and development, manufacture, and sale of ophthalmic medical materials in Taiwan and internationally.

ICARES Medicus Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ICARES Medicus
Historical stock prices
Current Share PriceNT$84.80
52 Week HighNT$103.00
52 Week LowNT$59.00
Beta0.57
1 Month Change3.04%
3 Month Change6.00%
1 Year Change32.71%
3 Year Change24.71%
5 Year Change68.92%
Change since IPO67.92%

Recent News & Updates

Shareholder Returns

6612TW Medical EquipmentTW Market
7D-3.0%-5.0%-4.7%
1Y32.7%-12.4%-19.9%

Return vs Industry: 6612 exceeded the TW Medical Equipment industry which returned -12.4% over the past year.

Return vs Market: 6612 exceeded the TW Market which returned -19.9% over the past year.

Price Volatility

Is 6612's price volatile compared to industry and market?
6612 volatility
6612 Average Weekly Movement5.4%
Medical Equipment Industry Average Movement5.5%
Market Average Movement5.0%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 6612 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6612's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aIh-Houng Lohhttps://www.icaresmedicus.com

ICARES Medicus, Inc., a nano-medical material company, focuses on the research and development, manufacture, and sale of ophthalmic medical materials in Taiwan and internationally. It provides ophthalmic medical materials, including intraocular lens for the treatment of cataract, myopia, hyperopia, presbyopia, or astigmatism; and surgical implantation systems, as well as related technical services. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

ICARES Medicus Fundamentals Summary

How do ICARES Medicus's earnings and revenue compare to its market cap?
6612 fundamental statistics
Market CapNT$2.90b
Earnings (TTM)NT$100.92m
Revenue (TTM)NT$457.85m

28.7x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6612 income statement (TTM)
RevenueNT$457.85m
Cost of RevenueNT$85.52m
Gross ProfitNT$372.33m
Other ExpensesNT$271.41m
EarningsNT$100.92m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.95
Gross Margin81.32%
Net Profit Margin22.04%
Debt/Equity Ratio0.4%

How did 6612 perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

17%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 6612 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6612?

Other financial metrics that can be useful for relative valuation.

6612 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.7x
Enterprise Value/EBITDA18.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 6612's PE Ratio compare to its peers?

6612 PE Ratio vs Peers
The above table shows the PE ratio for 6612 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average21.5x
1786 SciVision Biotech
27.7xn/aNT$3.0b
4129 United Orthopedic
24.6xn/aNT$2.4b
4155 OK Biotech
20.2xn/aNT$2.5b
4126 Pacific Hospital Supply
13.6x6.2%NT$4.9b
6612 ICARES Medicus
28.7xn/aNT$2.9b

Price-To-Earnings vs Peers: 6612 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the peer average (21.5x).


Price to Earnings Ratio vs Industry

How does 6612's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

Price-To-Earnings vs Industry: 6612 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the TW Medical Equipment industry average (18.8x)


Price to Earnings Ratio vs Fair Ratio

What is 6612's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6612 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6612's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 6612 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6612 (NT$84.8) is trading above our estimate of fair value (NT$11.23)

Significantly Below Fair Value: 6612 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is ICARES Medicus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


1.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ICARES Medicus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has ICARES Medicus performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


9.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6612 has high quality earnings.

Growing Profit Margin: 6612's current net profit margins (22%) are higher than last year (10.6%).


Past Earnings Growth Analysis

Earnings Trend: 6612's earnings have grown by 9.4% per year over the past 5 years.

Accelerating Growth: 6612's earnings growth over the past year (176.5%) exceeds its 5-year average (9.4% per year).

Earnings vs Industry: 6612 earnings growth over the past year (176.5%) exceeded the Medical Equipment industry 19%.


Return on Equity

High ROE: 6612's Return on Equity (9.6%) is considered low.


Discover strong past performing companies

Financial Health

How is ICARES Medicus's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 6612's short term assets (NT$572.8M) exceed its short term liabilities (NT$148.1M).

Long Term Liabilities: 6612's short term assets (NT$572.8M) exceed its long term liabilities (NT$16.6M).


Debt to Equity History and Analysis

Debt Level: 6612 has more cash than its total debt.

Reducing Debt: 6612's debt to equity ratio has reduced from 19.9% to 0.4% over the past 5 years.

Debt Coverage: 6612's debt is well covered by operating cash flow (2536.1%).

Interest Coverage: 6612 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is ICARES Medicus's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.59%

Current Dividend Yield

Dividend Yield vs Market

ICARES Medicus Dividend Yield vs Market
How does ICARES Medicus dividend yield compare to the market?
SegmentDividend Yield
Company (ICARES Medicus)0.6%
Market Bottom 25% (TW)2.5%
Market Top 25% (TW)7.0%
Industry Average (Medical Equipment)3.9%
Analyst forecast in 3 Years (ICARES Medicus)n/a

Notable Dividend: 6612's dividend (0.59%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.54%).

High Dividend: 6612's dividend (0.59%) is low compared to the top 25% of dividend payers in the TW market (6.96%).


Stability and Growth of Payments

Stable Dividend: 6612 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 6612 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: 6612 is not paying a notable dividend for the TW market.


Cash Payout to Shareholders

Cash Flow Coverage: 6612 is not paying a notable dividend for the TW market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Ih-Houng Loh

5.75yrs

Tenure

Mr. Ih-Houng Loh serves as Chairman of the Board and Chief Executive Officer since December 7, 2016 of ICARES Medicus, Inc. and has been its Director since July 14, 2011. Mr. Loh serves as Chairman of the...


Leadership Team

Experienced Management: 6612's management team is seasoned and experienced (5.7 years average tenure).


Board Members

Experienced Board: 6612's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 6612?
Owner TypeNumber of SharesOwnership Percentage
Institutions95,0110.3%
General Public34,068,88999.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 1 shareholders own 0.28% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.28%
KGI Securities Investment Trust Co. Ltd.
95,011NT$8.1m0%0.08%

Company Information

ICARES Medicus, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ICARES Medicus, Inc.
  • Ticker: 6612
  • Exchange: TPEX
  • Founded: 2011
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: NT$2.897b
  • Shares outstanding: 34.16m
  • Website: https://www.icaresmedicus.com

Number of Employees


Location

  • ICARES Medicus, Inc.
  • No. 16, Shengyi Road
  • 4th Floor
  • Zhubei
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6612TPEX (Taipei Exchange)YesOrdinary SharesTWTWDDec 2016

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/26 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.